Brezivaptan
![]() | |
Clinical data | |
---|---|
Other names | TS-121; TS121; TS-1211; TS1211; THY1773; THY-1773; ANC-501; ANC501 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H30ClN5O3 |
Molar mass | 484.00 g·mol−1 |
3D model (JSmol) | |
| |
|
Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5]
See also
[edit]References
[edit]- ^ PubChem. "Brezivaptan". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
- ^ a b "TS 121 -". AdisInsight. Springer Nature Switzerland AG.
- ^ a b "New Drug Pipeline - Taisho Pharmaceutical Holdings".
- ^ Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I (September 2020). "Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study". Journal of Psychiatric Research. 128: 43–51. doi:10.1016/j.jpsychires.2020.05.017. PMID 32521250. S2CID 219587135.
- ^ Inatani S, Mizuno-Yasuhira A, Kamiya M, Nishino I, Sabia HD, Endo H (May 2021). "Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data". Biopharmaceutics & Drug Disposition. 42 (5): 204–217. doi:10.1002/bdd.2273. PMC 8252455. PMID 33734452.
External links
[edit]- Clinical trial number NCT03093025 for "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder" at ClinicalTrials.gov